Greffex Dengue Vaccine
Dengue fever is an emerging infectious disease whose symptoms range from asymptomatic to severe forms (hemorrhagic fever and shock). The later typically present with broad capillary leakage and, in some cases, encephalitis, hepatitis, kidney failure and ultimately death. Only supportive therapy is presently available. Dengue viruses are transmitted by the mosquitoes Aedes aegypti and albopictus. As these insects have been spreading throughout the world, Dengue has developed into a growing threat in South Asia, Central and South America, and the Caribbean with a population of 2.5 billion at risk. The World Health Organization estimates that 500,000 cases of severe Dengue occur yearly with 22,000 deaths mostly in children.
Dengue fever outbreaks have been seen in US military personnel stationed in endemic regions. It is also found in US territories, the Virgin Islands, Puerto Rico, Hawaii, and Southern Florida.
Greffex has produced the Dengue vaccine GREDEN/V1-4™ using its GREVAX™ Universal Platform. GREDEN/V1-4 has been undergoing preclinical testing. It is being developed in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID).